Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-04-16 | Dr. Ramy FaridCEO, President & Director | -86,00k | 791,16k | Derivative Exercise and Sale | 3,07 - 12,33 | 272,72k | - |
| 2026-04-17 | Dr. Ramy FaridCEO, President & Director | 74,53k | 228,80k | Derivative Exercise and Retained Stock | 3,07 | 272,72k | 37,60% |
| 2026-04-16 | Mr. Richie JainExec. VP, CFO & Treasurer | -844,00 | 10,76k | Automatic Disposition | 12,75 | 6,26k | -11,89% |
| 2026-03-05 | Ms. Jenny HermanInsider | -1,38k | 17,76k | Automatic Disposition | 12,84 - 12,85 | 12,21k | -10,18% |
| 2026-03-05 | Ms. Yvonne TranCorporate Secretary, Chief Legal & People Officer | -1,09k | 14,11k | Automatic Disposition | 12,90 | 10,49k | -9,44% |
| 2026-03-05 | Mr. Richie JainExec. VP, CFO & Treasurer | -1,63k | 21,03k | Automatic Disposition | 12,90 | 4,60k | -26,18% |
| 2026-03-05 | Dr. Ramy FaridCEO, President & Director | -3,66k | 47,25k | Automatic Disposition | 12,91 | 198,19k | -1,81% |
| 2026-03-05 | Mr. Kenneth Patrick LortonExec. VP, CTO & COO of Software | -1,22k | 15,76k | Automatic Disposition | 12,90 | 40,01k | -2,96% |
| 2026-03-05 | Dr. Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships | -1,37k | 17,63k | Vendita | 12,90 | 6,41k | -17,56% |
| 2026-03-04 | Dr. Robert Lorne AbelExec. VP, Chief Scientific Officer of Platform and Head of Modeling R&D | -1,30k | 16,65k | Automatic Disposition | 12,81 | 6,07k | -17,63% |
| 2026-03-02 | Dr. Richard A. FriesnerCo-Founder, Scientific Advisory Chairman and Director | 160,53k | 492,82k | Derivative Exercise and Retained Stock | 3,07 | 1,40M | 12,96% |
| 2026-03-02 | Dr. Ramy FaridCEO, President & Director | -5,56k | 66,15k | Automatic Disposition | 11,90 | 192,48k | -2,81% |
| 2026-03-02 | Dr. Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships | -2,21k | 26,45k | Automatic Disposition | 11,99 | 3,87k | -36,30% |
| 2026-02-10 | Ms. Yvonne TranCorporate Secretary, Chief Legal & People Officer | -776,00 | 10,71k | Automatic Disposition | 13,80 | 8,46k | -8,40% |
| 2026-02-10 | Mr. Kenneth Patrick LortonExec. VP, CTO & COO of Software | -925,00 | 12,70k | Automatic Disposition | 13,73 | 38,11k | -2,37% |
| 2026-02-10 | Ms. Jenny HermanInsider | -752,00 | 10,37k | Automatic Disposition | 13,79 | 9,31k | -7,47% |
| 2026-02-09 | Dr. Robert Lorne AbelExec. VP, Chief Scientific Officer of Platform and Head of Modeling R&D | -1,23k | 16,62k | Automatic Disposition | 13,51 | 4,25k | -22,45% |
| 2025-10-16 | Dr. Margaret Han DuganInsider | -1,40k | 29,39k | Automatic Disposition | 21,07 | 4,57k | -23,37% |
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
